On Monday, Immunome Inc (NASDAQ: IMNM) was 5.78% up from the session before settling in for the closing price of $17.14. A 52-week range for IMNM has been $5.15 – $18.45.
A company in the Healthcare sector has dropped its sales by -38.15% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 56.02%. With a float of $83.71 million, this company’s outstanding shares have now reached $91.71 million.
Immunome Inc (IMNM) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Immunome Inc stocks. The insider ownership of Immunome Inc is 8.72%, while institutional ownership is 95.97%. The most recent insider transaction that took place on Jun 03 ’25, was worth 46,900. In this transaction Director of this company bought 5,000 shares at a rate of $9.38, taking the stock ownership to the 36,415 shares. Before that another transaction happened on Mar 25 ’25, when Company’s Director bought 7,800 for $7.78, making the entire transaction worth $60,684. This insider now owns 31,415 shares in total.
Immunome Inc (IMNM) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -1.11 earnings per share (EPS) during the time that was less than consensus figure (set at -0.61) by -0.5. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.59 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 56.02% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.42% during the next five years compared to -38.15% drop over the previous five years of trading.
Immunome Inc (NASDAQ: IMNM) Trading Performance Indicators
You can see what Immunome Inc (IMNM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 171.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.96, a number that is poised to hit -0.57 in the next quarter and is forecasted to reach -2.50 in one year’s time.
Technical Analysis of Immunome Inc (IMNM)
Let’s dig in a bit further. During the last 5-days, its volume was 1.83 million. That was better than the volume of 1.14 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 68.78%.
During the past 100 days, Immunome Inc’s (IMNM) raw stochastic average was set at 93.93%, which indicates a significant increase from 84.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.27 in the past 14 days, which was higher than the 0.82 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.72, while its 200-day Moving Average is $10.21. However, in the short run, Immunome Inc’s stock first resistance to watch stands at $18.83. Second resistance stands at $19.53. The third major resistance level sits at $20.27. If the price goes on to break the first support level at $17.39, it is likely to go to the next support level at $16.65. The third support level lies at $15.95 if the price breaches the second support level.
Immunome Inc (NASDAQ: IMNM) Key Stats
There are 91,710K outstanding shares of the company, which has a market capitalization of 1.66 billion. As of now, sales total 9,040 K while income totals -292,960 K. Its latest quarter income was 4,020 K while its last quarter net income were -43,400 K.
